Results 181 to 190 of about 7,735 (207)
Some of the next articles are maybe not open access.
Immunoconjugate Anticancer Therapeutics
2009Immunoconjugate therapy has entered the mainstream of cancer management with the regulatory approval and the bench to bedside transition of three antibody conjugates for lymphoma and leukemia. A number of antibody conjugates of radionuclides, drugs, and protein toxins are in various stages of clinical development.
Serengulam V. Govindan +1 more
openaire +1 more source
Targeted Drug Delivery Using Immunoconjugates
Journal of Immunotherapy, 2011Antibody-drug conjugates (also known as "immunoconjugates") have only recently entered the arsenal of anticancer drugs, but the number of undergoing clinical trials including them is ever increasing and most therapeutic antibodies are now patented including their potential immunoconjugate derivatives.
PASQUETTO, MARIA VALENTINA +4 more
openaire +3 more sources
Immunoconjugates: Current Status and Future Potential
Journal of Drug Targeting, 2002Whilst the concepts involved in immunoconjugates go back two centuries to the ideas of Ehrlich; it was only in the early 1980s that biotechnology gave us the tools to make pure immunoconjugates, in quantities sufficient for clinical studies [Garnett, M.C. (2002) "Targeted drug conjugates: principles and progress".
openaire +2 more sources
Potential Use of Immunoconjugates for AIDS Therapy
AIDS Research and Human Retroviruses, 1992More than a dozen of hybrid proteins possessing reactivity with human immunodeficiency virus-type 1-(HIV-1) infected cells and cytotoxicity have been produced and studied by several groups. These proteins are prepared either by chemical cross-linking of a toxin and a carrier molecule or by expressing fused genes of the two moieties.
Y W, Kim, T W, Chang
openaire +2 more sources
Stabilisation of immunoconjugates by trehalose
Biotechnology Letters, 2000Stable immunoconjugates were prepared in the presence of 400 mM trehalose. Their residual activity after freeze-drying, rehydration and incubation for 9 h at 40 °C was 35%. Freeze-dried conjugates containing 400 mM trehalose incubated at 40 °C for 4 days retained 80% of their original activity.
Maria Izabel Esteves +5 more
openaire +1 more source
Immunoconjugates of Carbon Nanostructures
2006For the first time, carbon nanostructures have been designed and synthesized to form immunoconjugates with monoclonal antibodies (mAb) for use in cell-targeted cancer diagnosis and therapy. The immunoconjugates are derived from various nanoscale carbon-based building blocks, specifically fullerenes (C60 ), gadofullerenes (M C60) and ultra-short carbon ...
openaire +1 more source
Tumour-targeted chemotherapy with immunoconjugates of calicheamicin
Expert Opinion on Biological Therapy, 2004Antibody-targeted chemotherapy is a therapeutic strategy in cancer therapy that involves a monoclonal antibody specific for a tumour-associated antigen, covalently linked via a suitable linker to a potent cytotoxic agent. Tumour-targeted delivery of a cytotoxic agent in the form of an immunoconjugate is expected to improve its antitumour activity and ...
openaire +2 more sources
Cytotoxic Effect of Binar Cisplatin Immunoconjugate
1998Increasing the effeciency of antitumoral therapy is connected, to a considerable degree, with creating and using perspective forms of antitumor preparations of a purposeful action. Platinum preparations relate to the effective group of cytostatic compounds, inhibitors of tumor and leukemic cell proliferation.
openaire +2 more sources
Immunoconjugates as Anti-Cancer Agents
1998In general, drug design in cancer therapy tends to focus on inhibiting cell growth. In cancer cells, there is abnormal growth activity which is often correlated with the high activity of certain proteins in the tumour cells. If such proteins can be identified and their role in cell growth verified, then limiting their activity by binding an inhibitor ...
Richard Pauptit +4 more
openaire +1 more source